Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 10, 2003. The report details changes in directors' interests in Ordinary Share American Depositary Receipts (ADRs) and Ordinary Shares resulting from dividend reinvestment and movements in the company's US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and director disclosures rather than consolidated financial performance.
Material Changes
- Dividend Reinvestment: Directors D F McHenry and J H McArthur increased their beneficial interests in Ordinary Share ADRs through the US Global BuyDirect Plan following the dividend paid on January 3, 2003. The purchase price was $39.0290 per ADR.
- Retirement Plan Movement: The GlaxoSmithKline US Retirement Savings Plan saw a decrease in held Ordinary Share ADRs from 18,320,180 to 18,281,390 on January 9, 2003, at an average price of $39.73.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a regulatory disclosure of specific shareholding changes.
Key Facts for Investor Verification
- Verify the impact of the dividend reinvestment plan on director ownership percentages.
- Confirm the average price of $39.73 for the Retirement Savings Plan transaction on January 9, 2003.
- Note that Directors Dr J P Garnier and Mr J D Coombe hold interests in the Retirement Savings Plan shares alongside other employees.